Abbott Laboratories ABT:NYSE (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
56.08 -0.24   -0.43%1.88%4,709,0455.3M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/23/2017 (03:59 PM 10/23/2017 Eastern Standard Time)

Latest News Headlines for Abbott Laboratories

A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott

ABBOTT HAS BEEN NAMED A TOP EMPLOYER BY SCIENCE, EVALUATED BY 6,950 PEOPLE IN SCIENCE FIELDS AROUND THE WORLD ABBOTT PARK, Ill., Oct. 19, 2017 /PRNewswire/ -- Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world.

Global Demand for Electrophysiology and Medical Devices Flourishing With Opportunities in Healthcare Sector

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Abbott Reports Third-Quarter 2017 Results

Divestiture- Initiatives Adjustment Devaluation Intangible Other Total related (a) (b) (c) (d) Amortization (e) Specifieds

View more recent headlines

Peers Information HelpABT Abbott Laboratories vs. Peers

Abbott Laboratories
Eli Lilly and Co
AstraZeneca plc (ADR)
Bristol-Myers Squibb Co
Novo Nordisk A/S (ADR)
Abbott Laboratories
Eli Lilly and Co
AstraZeneca plc (ADR)
Bristol-Myers Squibb Co
Novo Nordisk A/S (ADR)
Abbott Laboratories
Eli Lilly and Co
AstraZeneca plc (ADR)
Bristol-Myers Squibb Co
Novo Nordisk A/S (ADR)
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open56.21
Previous Close56.08
Day High56.685
Day Low56.07
52 Week High10/23/2017 | 56.685
52 Week Low12/1/2016 | 37.38
% Off 52 Week High-1.07%
% Off 52 Week Low50.03%
Beta (5 Yr)1.57
Volatility Avg10/23/2017 | 15.19
10-Day Avg. Volume5,321,100
Market data is delayed by at least 15 minutes.

expand, down-facing arrow indicating expanded view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2017 | 1.21
P/E Ratio9/30/2017 | 46.2
Market CapLarge Cap | 97.44B
Shares Outstanding1.74B

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield1.88%
Dividend Announcement9/14/2017
Date of Record10/13/2017
Payable$0.265 - QRTR
Payable Date11/15/2017

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short15.01M
Short Ratio2.0
Short % of Float0.87%
As of 9/29/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.